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ABSTRACT  Previous studies have established  a role for heparin-like molecules in the regulation 
of vascular smooth muscle cell growth and migration in vitro. We present data indicating that 
the secretory  phenotype of cultured  rat  aortic smooth  muscle  cells  can  be  modulated  by 
exogenous soluble heparin, heparan sulfate, and dermatan sulfate glycosaminoglycans.  In the 
presence  of these molecules, smooth muscle cells secrete increased amounts of two noncol- 
lagenous  proteins (Mr 37,000 and 39,000).  This effect can  be mimicked  by iota carrageenan 
and dextran sulfate but not by hyaluronic acid, chondroitin-4-sulfate, or chondroitin-6-sulfate. 
The inductive effect of heparin was dose-dependent and occurred rapidly (within  1 h) with 
maximal  induction (three- to fivefold over controls) occurring after 10-12 h of treatment. The 
effect was rapidly reversible (within  1 h) and was not altered in the presence  of actinomycin 
D, suggesting regulation at a posttranscriptional level. These data indicate that the biosynthetic 
expression  of specific smooth  muscle  cell  proteins may be determined, at least in  part,  by 
components of the smooth muscle cell extracellular matrix. 
Several biological activities of vascular smooth muscle cells 
(SMC) ~  appear to be regulated by heparin and related glycos- 
aminoglycans. Heparin has been shown to inhibit SMC mi- 
gration after the  wounding  of cell layers in  vitro (18),  to 
inhibit SMC proliferation in vitro (4,  13) and in vivo after 
arterial injury (8), and to inhibit SMC "modulation" from a 
contractile to a synthetic/growth factor-responsive phenotype 
(7). 
The importance of these findings is supported by indica- 
tions that inhibitory heparin-like molecules may normally be 
present  in  the  quiescent  vascular  wall.  Early studies  (11) 
demonstrated the production of heparin-like glycosaminogly- 
cans by the vascular endothelium in vitro. More recent studies 
have indicated that heparan sulfates derived from quiescent 
cultures of  aortic endothelium (5) and from confluent cultures 
of vascular smooth muscle cells (10) are potent inhibitors of 
SMC growth. A heparinase-degradable inhibitory activity was 
found to be released from endothelial cell cultures by the 
action of a  specific endoglycosidase (5) present in platelets 
(19) and in SMC (10). This enzyme liberates small heparan 
sulfate glycosaminoglycans, 8-12  saccharides in  length, by 
cleaving  larger  chains  at  glucuronyl-glucosamine linkages 
(19). The presence of this enzyme in the vessel wall, and the 
implied generation of active heparan  sulfates in  the  SMC 
t Abbrevation used in this paper."  SMC, smooth muscle cells. 
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matrix, have led to the development of a model for vascular 
SMC growth control in which matrix heparin-like glycosami- 
noglycans act as endogenous chalones (5). 
The mechanism(s) by which heparin inhibits SMC growth, 
migration, and "modulation" are not known. It is likely that 
heparin may elicit a pleiotropic response in vascular SMC; in 
the presence of heparan sulfate molecules in the SMC matrix, 
many functions associated with the differentiation of these 
cells may be affected. We have begun to analyze the role of 
these  matrix  molecules in  the  regulation  of SMC  protein 
synthesis and gene expression. We have found that heparin- 
treated rat SMC produce markedly increased amounts of a 
cell layer-associated collagenous protein with  a  molecular 
weight of 60,000 (17).  In this paper we describe changes in 
the pattern of secreted proteins after treatment of rat SMC 
with exogenous glycosaminoglycans, emphasizing the coor- 
dinately induced secretion of two noncollagenous polypep- 
tides (Mr 37,000 and 39,000).  Our observations suggest that 
the biosynthetic phenotype of vascular SMC may be deter- 
mined, at least in part, by the character of the SMC extracel- 
lular matrix. 
MATERIALS  AND  METHODS 
Cell Culture:  Rat SMC were grown from aortic explants essentially as 
described previously (18). Cultures were maintained  at 37*(2 in a humidified 
5% CO2 atmosphere in Waymouth's  medium (Rehatuin,  Reheis Chemical Co., 
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Systems, Inc., Logan, UT), 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 
0.4/tg/ml N-butyl-p-hydroxybenzoate. SMC were subcultured at a  1:4 split 
ratio; cells in the first through fifth pag~age were plated into 20- or 35-mm wells 
for metabolic labeling.  Except where indicated, only multi-layered, overcon- 
fluent SMC cultures were used in experiments. Under these conditions, SMC 
migration and proliferation were at minimal levels. 
GIycosaminoglgcan Treatment and  Metabolic Labeling: 
SMC cultures were exposed to soluble glycosaminoglycans  (usually at 100 ug/ 
ml) added to stock culture medium that contained 10% serum for indicated 
periods of time. No detectable morphological alterations followed treatment of 
SMC with giycosaminoglycans.  Heparin (type I, 167 United States Pharmaco- 
peia U/rag), hyaluronic acid and dextran sulfates were obtained from Sigma 
Chemical Co., St. Louis, MO. Low molecular weight non-anticoagulant  heparin 
(RD heparin) was provided by Hepar Industries, Franklin, OH. Iota carrageenan 
was a gift of Dr. T. Wight, University of Washington. Heparan sulfate (from 
bovine kidney), chondroitin-4-sulfate, chondroitin-6-sulfate,  and dermatan sul- 
fate were obtained from Miles Laboratories, Inc., Elkhart, IN. After exposure 
of SMC to glycosaminoglycans,  cells were metabolically labeled with 50 #Ci/ 
ml of [2,3-3H]proline  (Amersham Corp., Arlington Heights, IL; 33 Ci/mmol), 
40-60 ~Ci/ml [35S]methionine  (New England Nuclear, Boston, MA;  1166.5 
Ci/mmol), or 50 #Ci/rnl [5,6-3H]uridine  (Amersham Corp., 46 Ci/mmol) in 
Waymouth's medium lacking proline or methionine as required. All labeling 
media were  supplemented with  50  ~g/ml sodium ascorbate,  80  ~g/ml  B- 
aminopropionitrile fumarate, antibiotics, 0. l  mg/ml bovine serum albumin, 
and glycosaminoglycans  as indicated. Cells were labeled for  1-24 h  at 37°C. 
Actinomycin D (Sigma Chemical Co.) was used at 2.5-5/~g/ml. The efficacy 
of  actinomycin treatment was determined by incorporation of [3H]uridine  into 
RNA. 
Sample Preparation and SDS PAGE:  We harvested  metabolically 
labeled  culture medium into  protease inhibitors at  4"(2, producing a  final 
concentration of 0.2 mM phenylmethanesulfonyl fluoride,  10 mM N-ethyl- 
maleimide, 2.5 mM EDTA, and 3 vg/ml pepstatin. Proteins were then precip- 
itated  with  10%  triehloroacetic  acid.  Radio-labeled secreted  proteins were 
resolved by SDS PAGE according to Laemmli (14), using 8 or 10% separating 
gels that contained urea, and 3% stacking gels. Gels were processed for fluores- 
cence autoradiography by permeation with dimethyl sulfoxide and 2,5-diphen- 
yloxazole (3). Gels were then dried and exposed to x-ray film (Kodak X-Omat) 
at -70"C. All gels presented herein were run under reducing conditions (2 mM 
dithiothreitol). Quantitation of radioactivity incorporated into specific  bands 
was achieved by scanning underexposed gels (to insure linear conditions) with 
a Helena Quick-Scan gel scanner (Helena Laboratories, Beaumont, TX). 
RESULTS 
Overview of Heparin-induced Changes in SMC 
Secretory Phenotype 
When  rat  SMC  were treated  for  72  h  with  100  #g/ml 
heparin preceding a 24 h metabolic labeling with [3H]proline, 
several reproducible changes were observed in the pattern of 
proteins resolved by SDS PAGE. We have previously reported 
that  heparin-treated SMC  cell layers contain  markedly in- 
creased amounts of  a 60,000-mol-wt collagenous protein (l 7). 
Analysis of  proteins secreted into the culture medium revealed 
reduced secretion by heparin-treated cells of type III relative 
to type I procollagen (Fig.  l, left panel). This observation will 
be described in greater detail at a later time. 
Heparin-treated SMC secreted increased amounts of two 
polypeptide chains that were not detectable or barely detect- 
able in  [3H]proline-labeled control culture medium (Fig.  l, 
right  panel).  Under  reducing conditions,  these  chains  mi- 
grated on SDS  PAGE with apparent molecular weights  of 
37,000 and 39,000, according to globular protein standards. 
Data presented in this paper describe the kinetics and char- 
acteristics of the induction of these proteins by heparin. 
When SMC proteins were metabolically labeled with [35S]- 
methionine or [35S]cysteine, the Mr 37,000 and 39,000 pro- 
teins were consistently detected, in low amounts, in control 
FIGURE  I  Overview of heparin-induced  changes in SMC secretory 
phenotype. Rat SMC were cultured to overconfluence in 20-ram 
multiwell plates and then treated for 72 h in the presence of 10% 
fetal calf serum, with or without 100 ~.g/ml heparin. The cultures 
were subsequently labeled for 24 h with [3H]proline, in the pres- 
ence or absence of heparin. Medium proteins were harvested into 
protease inhibitors and resolved by SDS PAGE (8% separating gel) 
followed by fluorography. Both  panels represent  autoradiographs 
of the same gel, exposed to different densities for clarity of pres- 
entation. In the left panel (left  lane),  the relative densities  of the 
prod I (I) collagen band (identified by immunoprecipitation)  and the 
proal(lll)  collagen band are similar. In the presence of heparin (right 
lane), the proal(lll)  band is significantly  less intense. The right panel 
illustrates the induced secretion, in the presence of heparin, of two 
proteins with Mr 37,000 and 39,000. 
culture media (see Fig. 4). In addition, another heparin-related 
change in phenotype was observed. In the presence ofheparin, 
SMC released increased amounts of a protein with a reduced 
Mr of ~ 180,000;  this protein has been identified by immu- 
noprecipitation as thrombospondin. This effect (see Fig. 6) is 
currently under investigation.  Heparin-induced changes  in 
secretory phenotype were not observed in cultured human 
fetal foreskin fibroblasts or in bovine aortic endothelial cells. 
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wt Proteins 
At present, the nature of  the Mr 37,000 and 39,000 proteins, 
and the relationship between the two, are not clear. Neither 
protein was degraded when SMC medium was incubated with 
purified bacterial collagenase under conditions that permitted 
the selective digestion of known collagens (data not shown). 
Cross-incubation studies were performed to assess the possi- 
bility that the 37,000- and 39,000-mol-wt proteins were pro- 
duced by the action of heparin  on a  heparin-inducible or 
heparin-activated protease leading to cleavage of larger cellu- 
lar products. Control SMC were labeled with [35S]methionine 
and the media harvested, dialyzed to remove free methionine, 
lyophilized, redissolved in Waymouth's medium, and incu- 
bated with control or heparin-stimulated (24 h) SMC cultures 
for 2  h.  No detectable [35S]methionine-labeled  37,000- and 
39,000-mol-wt proteins were produced by the incubation of 
control, prelabeled medium  proteins with  heparin-induced 
cells.  It is also possible that the 37,000- and 39,000-mol-wt 
proteins are produced by heparin-activated proteolytic deg- 
radation of a  higher molecular weight, cell layer-associated 
protein. However, no change in cell layer proteins consistent 
with such an effect can be detected by SDS PAGE (see Fig. 
5). 
Glycosaminoglycan Specificity  of Induction of the 
37,000- and 39,000-mol-wt Proteins 
To determine the specificity of  the SMC response to various 
polyanions,  we  treated  SMC  cultures  with  100  ~g/ml  of 
soluble glycosaminoglycans for 72 h before metabolic label- 
ing.  Cultures were labeled with [3H]proline for 24 h  in the 
presence of the appropriate glycosaminoglycan. Control cells 
secreted little or undetectable amounts of the Mr 37,000 and 
39,000 proteins. These molecules were produced in significant 
amounts in  the  presence of heparin,  heparan  sulfate,  and 
dermatan sulfate (Fig.  2),  but not in the presence of other 
glycosaminoglycans (hyaluronic acid,  chondroitin-4-sulfate, 
and  chondroitin-6-sulfate). The inductive effect of heparin 
could be mimicked by low and high molecular weight forms 
of dextran sulfate and by iota carrageenan, a highly sulfated 
polyanion found in Gigartinalean red algae.  Low molecular 
weight RD heparin (Hepar, 67 United States Pharmacopeia 
U/rag) was also effective in inducing the production of the 
Mr  37,000  and  39,000  proteins,  indicating that  molecular 
determinants of the glycosaminoglycans, rather than antico- 
agulant activity, are responsible for the effects shown.  The 
purity of our heparin, heparan sulfate, and dermatan sulfate 
preparations was  ascertained by paper chromatography on 
cellulose acetate using  a  cadmium  acetate buffer.  Heparin 
and heparan sulfate migrated as distinct, separate bands; the 
dermatan sulfate migrated as one major band with a minor, 
more highly charged "shoulder." Studies to  determine the 
active moieties in these preparations are now on-going. 
Dose-Dependence of Induction of the 37,000- 
and 39,000-mol-wt Proteins by Heparin 
Next, we examined the dose-dependence of induction of 
the 37,000- and  39,000-mol-wt proteins. SMC were treated 
with  heparin,  at increasing concentrations (0.01-1,000 pg/ 
ml), during a 2-h labeling period with [3~S]methionine. Hep- 
arin was effective in stimulating increased production of the 
FIGURE 2  Glycosaminoglycan  specificity  of  induction  of  the 
37,000- and 39,000-mol-wt proteins. SMC cultures were treated,  as 
described in Fig. 1, with 100 p.g/ml of various glycosaminoglycans. 
[3H]Proline-labeled secreted  cell products were subsequently ana- 
lyzed by SDS PAGE (10% separating gel) and fluorography. Products 
from control SMC (lane I) and from SMC treated  with heparin (lane 
2),  heparan  sulfate  (lane  3),  chondroitin-4-sulfate  (lane  4),  and 
dermatan sulfate (lane 5) are shown. Note the induction of 37,000- 
and 39,000-mol-wt proteins by heparin and, to a lesser extent, by 
heparan  sulfate and dermatan sulfate. The effects  of other glycos- 
aminoglycans tested are given in the text. The position of migration 
of  molecular weight standards  (x  10  -3)  are  shown  to  the  right. 
Arrows indicate positions of the Mr 37,000 and 39,000 proteins. 
37,000- and 39,000-mol-wt proteins at concentrations as low 
as 0.01 ug/ml, with a maximal effect near 100 gg/ml (Fig. 3). 
It should be emphasized that commercially prepared heparin 
may contain only a small percentage of the moiety active in 
inducing the synthesis of the Mr 37,000 and 39,000 proteins. 
This point  has  been emphasized by Fritze and  Rosenberg 
(10),  who reported that SMC-derived heparan sulfates were 
40-fold more active in inhibiting the growth of cultured SMC 
than  was  commercial  heparin.  Purification  of the  active 
moiety from heparin preparations (in progress)  should result 
in a marked shift in the dose-response curve. 
1690  THE JOURNAL OF  CELL BIOLOGY . VOLUME 99,  1984 FIGURE  3  Dose-dependency of induction of the 37,000-  and 39,000-mol-wt proteins. SMC cultures were labeled with [35S]- 
methionine for 2 h  in the presence  of increasing amounts of heparin (concentrations indicated on abscissa). Medium proteins 
were resolved by SDS PAGE (10% separating  gel) followed by fluorography (left). Quantitation of the relative densities of the 
37,000-  and  39,000-mol-wt  protein  bands  is  presented  at  right.  Note that the  proteins are  significantly induced  at  heparin 
concentrations >0.1/~g/ml. 
Time Course of Induction of the 37,000- and 
39,000-mol-wt Proteins by Heparin 
The time course of action of heparin on induction of the 
37,000- and  39,000-mol-wt proteins was determined by in- 
cubating SMC cultures with 100 #g/ml heparin from 0-22 h, 
then metabolically labeling the cells with [35S]methionine  for 
2 h  in the absence or presence of heparin. As presented in 
Fig.  4, secretion of the Mr 37,000 and  39,000 proteins was 
coordinately induced within 2 h of heparin treatment. Other 
experiments (not  shown)  have  demonstrated  induction  of 
these molecules within 1 h of heparin addition. In the contin- 
ued presence of heparin, 37,000- and 39,000-mol-wt protein 
synthesis  increased  to  maximally induced  levels  of up  to 
fivefold over control values. In some experiments, induction 
of  both proteins occurred to a similar extent (see Figs. 1, 3, 6, 
and 7); in most experiments the 37,000-mol-wt protein was 
induced to a greater extent than was the 39,000-mol-wt pro- 
tein (see Figs. 2, 4, and 5). Maximal induction was achieved 
after 10-12 h ofheparin treatment. 
Analysis of Possible Heparin-mediated Release of 
the 37,000- and 39,000-mol-wt Proteins from the 
Cell Layer Compartment 
Our time course experiments indicated that heparin-treated 
SMC secrete increased amounts of 37,000- and 39,000-mol- 
wt proteins within 1 h of heparin addition. We examined the 
possibility that this rapid secretion was effected by release of 
these molecules from either the extracellular matrix or from 
an intracellular pool of normally synthesized but not secreted 
proteins. As shown in Fig. 5 (lanes I and 2), no change in cell 
layer proteins could be detected after metabolic labeling with 
[35S]methionine for 2 h in the presence of heparin, suggesting 
that  the  37,000-  and  39,000-mol-wt  polypeptides  are  not 
major cell layer proteins that are displaced by heparin. This 
conclusion is supported by experiments in which we analyzed 
the ability ofheparin to release prelabeled 37,000- and 39,000- 
mol-wt proteins into the culture medium. SMC were prela- 
beled with [35S]methionine  for 2 h in the absence of heparin. 
The label was then chased with or without heparin in medium 
that contained a 10-fold excess of nonradioactive methionine; 
after 4  h,  the  chase  medium  was  collected and  analyzed. 
During  the  4  h-chase period,  SMC  released <10%  of the 
amount of acid-precipitable radioactivity released by the cells 
during the  2-h pulse period. Consequently, the  fraction of 
medium proteins required to provide equal numbers of  counts 
in lanes 5 and 6 in Fig. 5 was considerably greater than that 
required for lanes 3 and 4. The small increase in the density 
of the 37,000-mol-wt protein band observed when heparin 
was present during the chase period (Fig.  5, lane 6) can be 
attributed to an induction of this protein in the presence of 
residual-free methionine.  These data  indicate that  heparin 
treatment of SMC does not induce significant secretion or 
release of these molecules from stable, constantly synthesized, 
cellular storage pools. 
However, it is possible that, before secretion, SMC contin- 
ually synthesize and rapidly degrade the 37,000- and 39,000- 
mol-wt  proteins.  In  this  case,  one  could  hypothesize that 
heparin induces SMC to shunt specific intracellular vesicles 
to the plasma membrane rather than to lysosomes. It is also 
conceivable that heparin may inhibit the normal incorpora- 
tion of nascent 37,000- and 39,000-mol-wt proteins into the 
cell layer compartment, but is unable to effect release of  these 
h/~AIACK  AND BORNSTEIN Heparin  and Smooth  Muscle Cell Phenotype  1691 FIGURE 4  Time course of induction of the 37,000-  and 39,000-mol-wt proteins by heparin. SMC cultures were treated with 100 
#glml  heparin for the times  indicated. For each  time point, cells  were labeled  with [3SS]methionine for the final 2  h of each 
treatment period. Medium proteins were resolved by SDS PAGE (10% separating gel) followed by fluorography (/eft). Quantitation 
of the relative densities of the 37,000- and 39,000-mol-wt protein bands is presented at right. Note that induction of both proteins 
occurs within 2 h and reaches maximal levels after 10-12 h of heparin treatment. 
molecules subsequent to their deposition. While we cannot 
conclusively  eliminate  these  possibilities,  we  feel  that  the 
available data support our conclusion that the increased ap- 
pearance of the  37,000- and 39,000-mol-wt polypeptides in 
the culture medium results from enhanced synthesis of these 
proteins. 
Rapidity of Deinduction of the 37,000- and 
39,000-mol-wt Proteins  after Heparin Removal 
To determine the duration of the heparin effect, SMC were 
treated with heparin (100 #g/ml) for 2 h; the cells were then 
washed and re-fed fresh control medium for 1 or 3 h followed 
by metabolic labeling  with  [35S]methionine  for 2  h  in  the 
absence of heparin. As shown in Fig. 6, the effect of heparin 
on secretion of 37,000- and 39,000-mol-wt proteins was com- 
pletely reversible within  1 h  after removal of heparin from 
the cultures. These data indicate the short-lived nature of this 
SMC response to heparin; cells must be continuously exposed 
to heparin to maintain a  continuously high level of 37,000- 
and 39,000-mol-wt protein production. 
Also shown in Fig. 6 is the effect of heparin on the release 
(and possibly the synthesis) of a protein with a reduced Mr of 
180,000.  This protein, identified as thrombospondin, is pres- 
ent in increased amounts in media from cells pre-treated with 
heparin (lanes 3 and 4). 
Actinomycin D Sensitivity of Induction of the 
37,000- and 39,000-mol-wt Proteins by Heparin 
To determine if the heparin effect on SMC protein induc- 
tion was mediated at a transcriptional or posttranscriptional 
level, we stimulated SMC with heparin for 2 h in the presence 
or  absence  of 2.5  or  5  #g/ml  actinomycin  D,  a  specific 
inhibitor of DNA-dependent RNA synthesis. Control experi- 
ments indicated that, over a 2.5 h period, total RNA synthesis 
(expressed as [3H]uridine incorporation per microgram RNA) 
was significantly reduced in the presence of 2.5 or 5.0 #g/ml 
actinomvcin D  (<30% and <20%  of control value, resrmc- 
tively).  As  shown  in  Fig.  7,  induction  of the  37,000-  and 
39,000-mol-wt proteins by heparin in the first 2 h  following 
heparin treatment was not significantly reduced in the pres- 
ence of actinomycin D  at either concentration.  These data 
indicate that the initial induction of these proteins by heparin 
is not dependent upon new synthesis of RNA, suggesting that 
regulation of these proteins by heparin occurs at a posttran- 
scriptional level. 
DISCUSSION 
In this paper we demonstrate a direct effect of soluble matrix 
molecules on the expression of specific proteins by rat vascular 
SMC. In particular, we show that when SMC are cultured in 
the presence of heparin, heparan sulfate, or dermatan sulfate, 
the  production  of two  secreted  proteins  (Mr  37,000  and 
39,000) is coordinately induced. Other changes in the biosyn- 
thetic phenotype of these  cells in  response to  heparin  also 
occur (17;  manuscripts in preparation) and are not detailed 
here. Cochran et al. (9)  have reported that heparin inhibits, 
in a transitory fashion, the synthesis of a 48,000-mol-wt cell 
layer protein by rat aortic SMC and stimulates the secretion 
of a  35,000-mol-wt  medium  protein.  The  relationship  be- 
1692  THE JOURNAL  OF  CELL  BIOLOGY - VOLUME  99,  1984 FIGURE 5  Analysis  of  possible  heparin-mediated  release  of  the  37,000-  and  39,000-mol-wt  proteins  from  the  cell  layer 
compartment.  Lanes 1-4: SMC cultures were labeled for 2  h with [35S]methionine  in the absence  (lanes  1 and 3) or presence 
(lanes 2 and 4) of 100/~g/ml  heparin. Cell layer (lanes 1 and 2) and medium proteins (lanes 3 and 4) were resolved  by SDS PAGE 
(10% separating  gels) followed by fluorography. Note that the appearance  of the 37,000-  and 39,000-mol-wt proteins in the 
culture medium (lane 4) does not coincide with a detectable change in cell layer proteins (lane 2). Lanes  5 and 6: SMC cultures 
were metabolically labeled with [3SS]methionine for 2 h in the absence of heparin, and then rinsed and incubated with medium 
unlabeled for 4 h in the absence  (lane 5) or presence  (lane 6) of heparin. Note that heparin does  not significantly increase the 
amount of prelabeled 37,000-  and 39,000-mol-wt proteins appearing in the culture medium if present only during the 4 h chase 
period (compare  with lanes 3 and 4); equal amounts of radioactivity were loaded onto each lane. These data indicate that heparin 
does not release significant amounts of these proteins from a stable, preformed cellular or matrix pool. Positions of migration of 
the 37,000-  and 39,000-mol-wt proteins are indicated for each pair of lanes that were run on different gels. 
tween this 35,000-mol-wt protein and the 37,000- and 39,000- 
mol-wt proteins described in this work remains to be estab- 
lished.  These observations,  together with those data docu- 
menting the inhibitory effects of heparin on SMC growth (4, 
5, 8,  13) and migration (18), suggest a major role for endog- 
enous heparin-like molecules in determining the functional 
characteristics of vascular SMC. 
Modulation of SMC activity and phenotype may be  an 
important factor in determining, at least in part, the vascular 
response to atherogenic injury. Such a response might depend 
on a number of factors, including the presence of stimulatory 
growth factors, heparin-like inhibitors, and molecules capable 
of  binding (and perhaps inactivating) endogenously  produced 
heparan sulfates (5). Our data suggest that modulation be- 
tween control and heparin-induced phenotypes can occur very 
rapidly; the data for heparin inhibition of migration appear 
to be similar (18). The relationship between the induction of 
specific SMC proteins and the inhibition of growth and/or 
migration by heparin is not yet known. It is possible that the 
37,000-  and  39,000-mol-wt  proteins  described  herein,  the 
60,000-mol-wt  collagenous cell  layer protein (17), or other 
undetected heparin-inducible proteins may be causally related 
to these inhibitory activities. We have observed (unpublished 
observations)  that production of  the 37,000- and 39,000-mol- 
wt proteins is not increased in cells growth-arrested for 96 h 
in plasma-derived serum, indicating that the induction is not 
a  consequence of the inhibition of growth or migration by 
heparin. 
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FIGURE 7  Actinomycin sensitivity  of induction of the 37,000- and 
39,000-mol-wt proteins by heparin.  SMC cultures  were either not 
treated or pretreated for I h with 2.5 #g/ml or 5.0 #g/ml actinomycin 
D before metabolic labeling  with [3SS]methionine in the absence or 
presence of 100 #g/ml heparin. Medium proteins were then sub- 
jected to SDS PAGE, fluorography, and quantitative gel scanning. 
The relative areas under the 37,000- and 39,000-mol-wt peaks for 
each  experimental condition are presented.  Note the  failure of 
actinomycin D treatment to inhibit the inductive effects of heparin 
at this early time period. 
FIGURE 6  Rapidity of deinduction of the 37,000- and 39,000-mol- 
wt  proteins  after  heparin  removal.  Proteins  resolved  in  lane  l 
represent  secreted  proteins  from  control  cultures  metabolically 
labeled for 2 h with [3SS]methionine. When cultures are labeled for 
2 h in the presence of 100 #g/ml heparin (lane 2), the 37,000- and 
39,000-mol-wt proteins are induced. Lanes 3 and 4 illustrate  pro- 
teins secreted by cells treated with 100 #g/ml heparin for 2 h, then 
incubated I  h (lane 3) or 3 h (lane 4)  in the absence of heparin 
followed by a 2-h metabolic labeling  also in the absence of heparin. 
Note  that  cells  labeled  I-3  h  after  removal of  heparin do  not 
produce appreciable amounts of the 37,000-  and 39,000-mol-wt 
proteins. Arrow indicates the position of thrombospondin (reduced 
M, ~ 180,000). 
The failure of actinomycin D to inhibit the increased syn- 
thesis  of the  Mr  37,000  and  39,000  proteins supports the 
hypothesis that the expression of these proteins is regulated 
by heparin at a posttranscriptional level.  This conclusion is 
also supported by the rapid kinetics of induction and dein- 
duction. In other experiments (unpublished observations) we 
have observed that actinomycin D  treatment selectively re- 
duced production of the 37,000- and 39,000-mol-wt proteins 
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over a  30-h period, suggesting  that some form of transcrip- 
tional control may be superimposed on the  initial transla- 
tional or posttranscriptional control operative at early time 
points of induction. Analysis of polysomal and total mRNA 
from control, 2-h heparin-induced cells,  and  24-h heparin- 
induced cells might clarify the mechanisms of regulation of 
these proteins. 
Our observations are also significant, in a broader sense, in 
view of current interest concerning the proposed role of the 
extracellular matrix in the regulation of cellular growth (2, 
12), biosynthetic phenotype (l 5, 16), and gene expression (see 
reference l for review). In our studies, we have added exoge- 
nous glycosaminoglycans, in a soluble form, to SMC culture 
media and have observed very rapid phenotypic modulation. 
How is  this  regulation effected? A  number  of possibilities 
exist: (a) Heparin may interact with other matrix molecules 
to effect changes in  SMC cell shape by virtue of the close 
association between the extracellular matrix and the internal 
cytoskeleton. Such cell shape changes may alter the biosyn- 
thetic phenotype through differential association of specific 
mRNA species with the cytoskeleton (1). Note, however, that 
the cells  used in these experiments are overconfluent, sur- 
rounded by a dense matrix, and exhibit no detectable change 
in morphology in response to heparin (unpublished observa- 
tions).  (b)  Heparin  may interact with  the  cell  surface  via 
receptors and elicit a "second messenger" response intracel- 
lularly.  (c)  Heparin  may be  internalized by fluid-phase or 
receptor-mediated endocytosis and delivered to an intracel- 
lular site of action. Evidence for the binding and uptake of 
heparin by SMC in culture has recently been presented (6); 
these  authors  reported that  internalization of heparin  was 
rapid (within  15  min) and occurred, at least in part, via a 
coated vesicle pathway. 
The effects of heparin on vascular smooth muscle cells are 
cell-specific,  glycosaminoglycan-specific, and  varied  in  the 
range of biological responses effected. Heparin-like molecules 
are now known to regulate the proliferative capacity of SMC (4, 5, 8,  13), the rate of migration following in vitro experi- 
mental wounding (18), the "modulation" of SMC to a growth- 
factor  sensitive  phenotype  (7),  and  the  SMC  biosynthetic 
phenotype (9, 17; this paper). We therefore envision the effects 
of heparin  on  vascular  SMC  to  be  pleiotropic  in  nature, 
possibly reflecting the characteristics of a separate and specific 
heparin-induced SMC phenotype. 
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